Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
13.55B
Market cap13.55B
Price-Earnings ratio
-54.01
Price-Earnings ratio-54.01
Dividend yield
Dividend yield
Average volume
437.75K
Average volume437.75K
High today
$226.01
High today$226.01
Low today
$220.22
Low today$220.22
Open price
$225.00
Open price$225.00
Volume
80.24K
Volume80.24K
52 Week high
$248.60
52 Week high$248.60
52 Week low
$124.06
52 Week low$124.06

ASND News

TipRanks 3h
Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 18h
Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.

Ascendis Pharma (ASND) announced that Yuviwel was granted orphan drug exclusivity by the FDA and that Yuviwel is now commercially available in the United States...

Simply Wall St 1d
A Look At Ascendis Pharma Valuation After Key TransCon Trial Successes And Yuviwel FDA Approval

Ascendis Pharma (NasdaqGS:ASND) has drawn fresh attention after positive Week 52 Phase 2 New InsiGHTS data for TransCon hGH in Turner syndrome and long term App...

A Look At Ascendis Pharma Valuation After Key TransCon Trial Successes And Yuviwel FDA Approval

Analyst ratings

94%

of 18 ratings
Buy
94.4%
Hold
0%
Sell
5.6%

More ASND News

Simply Wall St 6d
Is It Time To Reassess Ascendis Pharma After Its Strong Multi‑Year Share Price Run?

If you are wondering whether Ascendis Pharma's share price still offers value after a strong run, the key is to look closely at what the current valuation actua...

Is It Time To Reassess Ascendis Pharma After Its Strong Multi‑Year Share Price Run?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.